drugset
drugset / Trial / NCT07052032

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

NCT07052032 ↗

Phase 1 Active not recruiting 47 enrolled Candid Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.

Timeline

Start
2025-06-16
Primary completion
2027-06-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CND261 Unknown — —

Indications

rheumatoid arthritis